Newron plans US clinical trial of anti-schizophrenia drug
This article was originally published in Scrip
Executive Summary
Newron Pharmaceuticals has submitted an IND application to the US FDA to begin a Phase I trial of NW-3509, which the Italian firm claims is the first selective, voltage-gated sodium channel (VGSC) modulator being developed for the treatment of schizophrenia.